+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID04643002

Study of Isatuximab With or Without Dexamethasone Combined With New Agents Compared to Isatuximab, Pomalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Led by Sanofi · Updated on 2026-10-13

258

Participants Needed

25

Research Sites

31 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating isatuximab combined with new agents, with or without dexamethasone, in participants who have relapsed or refractory multiple myeloma. This umbrella study includes several substudies Substudy 01 serves as the control, Substudies 02, 03, and 06 are controlled experimental arms, and Substudies 04 and 05 are independent experimental arms. The goal is to assess different combinations of treatments to determine safe doses and response rates in this patient population. Participants receive various combinations of isatuximab administered intravenously weekly for the first four weeks, then every two weeks in subsequent cycles. Depending on the substudy, treatments include oral dexamethasone weekly, oral pomalidomide daily for 21 days per cycle, and other intravenous or oral novel agents such as SAR439459, belantamab mafodotin, pegenzileukin, belumosudil, and evorpacept, each with specific dosing schedules. Treatment continues until disease progression, unacceptable side effects, participant choice, investigator decision, or study end, up to approximately 28 months. During the study, participants undergo regular assessments including measuring response rates, adverse events, quality of life questionnaires, bone pain scales, and pharmacokinetic sampling. These evaluations occur at baseline, throughout treatment cycles, and at follow-up visits. The research team monitors disease status and treatment effects over time to gather comprehensive data on safety and activity of the different drug combinations. Participants may be involved for up to 28 months, with ongoing monitoring until study completion.

CONDITIONS

Brief Title

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Research Team

T

Trial Transparency email recommended (Toll free number for US & Canada)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here